SAT0157 MYCOBACTERIUM TUBERCULOSIS SPECIFIC RESPONSES FROM CD8+ AND CD4+ T CELLS IN PATIENTS WITH LATENT AND ACTIVE FORM OF TUBERCULOSIS
Background: Testing the presence of latent or active tuberculosis using IGRA tests is necessary part of the diagnostic screening at risk individuals. QuantiFERON-TB Gold Plus (QFT-Plus) is a test for cell-mediated immune (CMI) responses to peptide antigens that simulate mycobacterial proteins. Peptide antigens in TB1 tube elicit CMI responses from CD4+ T-helper lymphocytes, in TB2 tube from CD8+ T-cytotoxic lymphocytes. Test is based on the ability of effector T lymphocytes to produce the cytokine interferon gamma (IFN-γ). Objectives: To compare and evaluate levels of IFN-γ produced by CD4+ and CD8+ cells in TB1 and TB2 tubes. Methods: It was studied 33 subjects with latent form of tuberculosis (LTBI) and 33 subjects with active TB. QFT-Plus was used to detect in vitro responses to peptide antigens associated with Mycobacterium tuberculosis infection (ELISA, QIAGEN). Results were obtained by calculation of INF-γ levels in Mitogen, TB antigen (TB1, TB2) and Negative control tubes using QFT analysis software. Results: QFT-Plus positive results were observed in both groups of people. Increased levels of IFN-γ produced by CD4+ cells (TB1) has been detected in 21 subjects with LTBI (63,64%) and in all 33 subjects with active TB (100,0%). Increased levels of IFN-γ produced by CD8+ cells (TB2) has been detected in 27 people with LTBI (81,82%) and in all 33 people with active TB (100,0%). Joint increase levels of IFN-γ in the tubes TB1 and TB2 was observed in 16 individuals with LTBI (48,48%) and in all 33 individuals with active TB (100,0%). In the group of patients with a negative QFT-Plus it was not observed increased levels of IFN in tubes TB1 and TB2. Conclusions: Our findings confirm specific CD4+ and CD8+ T cell response to mycobacterial protein antigens in individuals with LTBI and also in active TB subjects, in which INF-γ was frequently found. The immunological response represented by CD4+ and CD8+ T cells was not detected in subjects with QFT-Plus negative. Background: The strategy for the choice of the second biologic agent after the failure of the first TNF inhibitor (TNFi) is still an unclear aspect in the treatment of both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Switching between structurally different TNFis (from etanercept [ETN] to monoclonal antibody [mAb] or vice versa) has been proposed as a more effective procedure than switching among different mAbs, but to date no study has been specifically focused on exploring this topic. Objectives: To evaluate the comparative 2-year retention rate and the 12-month efficacy of adalimumab (ADA) as second biologic agent in etanercept (ETN) non-responder RA and PsA patients in a multicentre retrospective study. Methods: All RA and PsA patients from 11 Italian Rheumatology Units treated with ADA after a first-course ETN failure and with at least 12-month follow-up were retrospectively collected in a multicentre registry. Data analysis was limited to the period from January 2002 to May 2016. Two-year ADA retention rate was calculated by Kaplan-Meier method. 12-month ADA response was defined as achievement of disease activity score 28 calculated by using erythrosedimentation (DAS28-ESR) <2.6 (remission) or >2.6 and <3.2 (low disease activity, LDA Objectives: The purpose of this study was to examine the effectiveness of ADA on rheumatoid arthritis (RA) treatment course in the context of PSP participation. Methods: PASSION (NCT01383421) was a 78-week (wk) post-marketing observational study of pts with RA receiving ADA in routine clinical care. Pts from the EU, Israel, Mexico, Puerto Rico, and Australia with an insufficient response to ≥1 disease-modifying antirheumatic drug (DMARD) newly initiating ADA (1 prior biologic DMARD was allowed) were enrolled. The primary endpoint was the % of pts achieving the minimal clinically important difference (MCID; improvement of ≥0.22 compared to baseline [BL] ) in the Health Assessment Questionnaire Disability Index (HAQ-DI) at wk 78. Non-responder imputation (NRI) was used to account for the missing values. Secondary clinical parameters included % of pts achieving MCID in HAQ-DI at wks 24 and 52 and changes in the 28-joint DAS based on CRP (DAS28(CRP)), Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) at wks 24, 52, and 78 vs BL. Pts were categorized based on their participation in the PSP: ever (PSP users) vs never (PSP non-users) (Figure) . Study discontinuation rates were significantly (P<0.001) lower among PSP-users vs PSP non-users (25.5% vs 41.6%). Reasons for discontinuations are listed in the Table. Conclusions: The final study results showed that, in pts with moderate to severe RA who initiated ADA, significantly better improvement in functional and clinical outcomes was achieved in the PSP users vs the PSP non-users. Improvements were achieved at early timepoints and continued to increase throughout the study. Table 1 . Immunogenicity of biosimilars approved for the treatment of inflammatory rheumatic diseases. ADA: antidrug antibody, NA: not available, nADA: neutralizing antidrug antibody. *The EGALITY study presented a four-arm design in which two arms were continuously treated with either reference etanercept or GP2015 and the other two arms were systematically switched. The results presented in this table concern the groups continuously treated with reference etanercept or GP2015
Conclusions: Currently approved biosimilars for the treatment of rheumatic diseases have comparable immunogenicity profiles in respect to their reference drugs. The discrepancy in ADA between SB4 and reference etanercept did not correlate with efficacy or safety and did not preclude biosimilarity, according to the regulatory agencies. The higher proportion of ADA compared to historical data may be explained by the greater sensitivity of current immunogenicity assays, such as electrochemiluminescence. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.2486
